This trial is testing whether CHF 5993 is more effective than CHF 1535 at improving lung function, reducing exacerbations of COPD, and improving other clinical outcomes.
1 Primary · 20 Secondary · Reporting Duration: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52
Active Control
Experimental Treatment
2934 Total Participants · 2 Treatment Groups
Primary Treatment: Beclomethasone Dipropionate · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Florida | 50.0% |
Alabama | 25.0% |
Missouri | 25.0% |
18 - 65 | 50.0% |
65+ | 50.0% |
Chiesi Clinical Trial Site 840206 | 100.0% |
Met criteria | 75.0% |
Did not meet criteria | 25.0% |